Record Surge: Sage Shares Soar Following $400 Million Buyback Announcement

Sage Therapeutics, a leading biopharmaceutical company, has recently made headlines after announcing a substantial $400 million stock buyback. This strategic move sent the company's shares skyrocketing to an all-time high, showcasing market confidence in Sage's future prospects and commitment to enhancing shareholder value.

Continue reading